TACSTD2 and triple-negative breast carcinoma: Since the initial approval of TrodelvyTM for the treatment of triple-negative breast cancer (TNBC) and mUC, a range of Trop2-directed therapies with different MOAs and safety profiles have been developed (Figure 1).